Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels.
Patients with cor pulmonale and high hematocrit levels are often subjected to phlebotomy in the belief that the adverse effects of high viscosity may outweigh the benefit of increased oxygen carrying capacity. To evaluate this, 12 patients with stable cor pulmonale and hematocrit values greater than 55 per cent were studied before and after a series of venesections. Right heart and aortic pressures, cardiac output and blood gases were measured at three mean hematocrit levels, 61 per cent (stage I), 50 per cent (stage II) and 44 per cent (stage III), with blood volume unchanged. From stages I to II, there were significant decreases in both man pulmonary artery pressure and total pulmonary resistance. Oxygen transport fell but not oxygen consumption. Right ventricular end-diastolic pressure and cardiac output did not change. Right ventricular work either fell or was maintained by increased output. Frank-Starling performance (supine exercise) improved. No significant changes occurred with further reduction in hematocrit to normal levels (stage III). The findings of this study support the concept of overcompensating erythrocytosis in cor pulmonale, and the effects of moderate hematocrit reduction should not be overlooked in these severely ill patients.
D000328:Adult; D001794:Blood Pressure; D001809:Blood Viscosity; D001810:Blood Volume; D001815:Bloodletting; D002302:Cardiac Output; D005260:Female; D006339:Heart Rate; D006400:Hematocrit; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption; D005082:Physical Exertion; D011086:Polycythemia / Q000209:etiology / Q000628:therapy; D011651:Pulmonary Artery / Q000503:physiopathology; D011660:Pulmonary Heart Disease / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D014655:Vascular Resistance